BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and SK Capital will acquire Bluebird Bio for about $30M in upfront cash, or $3 per share, in addition to $6.84 per share in a contingent value right.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
- Bluebird Bio trading resumes
- Bluebird Bio trading halted, volatility trading pause
- Bluebird Bio downgraded to Neutral from Outperform at Baird
- Morning Movers: Bluebird Bio shares tumble following take-private deal